BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Must-See Attractions in France - 2See a half-lit moon shine among the stars of Aquarius on Nov. 27
- 3The Electric Bicycle Americans Can Confide in 2024
- 4A definitive Manual for Smart dieting on a Tight spending plan
- 5Parents search for children missing since a volcanic eruption in Colombia 40 years ago
- Vote in favor of the Top Vegetable for Senior
- Authorities arrest 7 bodyguards in connection with a Mexican mayor's assassination
- Why the chemtrail conspiracy theory lingers and grows – and why Tucker Carlson is talking about it
- Sally Rooney books may be withdrawn from UK sale over Palestine Action ban, court told
- Creativity Revealed: A Survey of \Making Shocking Looks\ Cosmetics Item
- Careful Living: Embracing the Current Second
- Figure out How to Consolidate Cutting edge innovations in Senior's SUVs
- Benedict Cumberbatch on letting go after a heavy role — and finding joy in ‘Elf’
- Vote In favor of Your Number one Savvy Beds
